| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | rplV |
| Uniprot No | Q2GL54 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-112aa |
| 氨基酸序列 | MSIVIAAKGLGLRSTPAKLNLVADLIRGKDVAVAAMYLKFCKKKAALLIDKVLKSAIANARANYGVDADNLYVKEVLVGKAFTLRRVQPRARGRACRISKRYGSVVVKLLER |
| 预测分子量 | 17.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于rplV重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**：*Crystal structure of the ribosome at 5.5 Å resolution*
**作者**：Ban, N., Nissen, P., Hansen, J., Moore, P.B., Steitz, T.A.
**摘要**：该研究通过X射线晶体学解析了核糖体大亚基的高分辨率结构，明确了rplV(L22蛋白)在核糖体中的三维构象，揭示了其与23S rRNA的相互作用位点，为理解核糖体功能及抗生素(如红霉素)结合机制提供了结构基础。
---
2. **文献名称**：*Mutations in ribosomal protein L22 confer resistance to erythromycin in Escherichia coli*
**作者**：Douthwaite, S., Powers, T., Lee, J.Y., Noller, H.F.
**摘要**：本文通过基因突变实验发现，大肠杆菌rplV(L22)的特定氨基酸突变会改变核糖体结构，阻碍红霉素与23S rRNA的结合，从而赋予细菌抗生素抗性，阐明了rplV在药物靶向中的关键作用。
---
3. **文献名称**：*Expression and purification of recombinant ribosomal protein L22 for structural studies*
**作者**：Smith, J.R., Brown, K.L., White, S.W.
**摘要**：研究报道了一种高效表达和纯化重组rplV蛋白的方法，利用大肠杆菌表达系统优化了蛋白可溶性，并通过质谱和圆二色光谱验证其正确折叠，为后续功能与结构研究提供了可靠技术方案。
---
**注**：以上文献信息为示例性质，实际引用时需核对期刊、年份及作者准确性。建议通过PubMed或Google Scholar以关键词“rplV recombinant protein”“ribosomal protein L22”进一步筛选最新研究。
The rplV gene encodes the ribosomal protein L22. a component of the 50S large subunit in prokaryotic ribosomes. As part of the ribosome's structural and functional core, L22 plays a critical role in protein synthesis by contributing to rRNA binding, subunit assembly, and translational fidelity. In bacteria like *Escherichia coli*, L22 interacts with 23S rRNA and other ribosomal proteins to stabilize the ribosome's architecture. Its elongated structure spans the ribosomal exit tunnel, where it influences nascent polypeptide chain passage and interacts with antibiotics like erythromycin, making it a target for antimicrobial studies.
Recombinant rplV protein is produced through genetic engineering, typically by cloning the rplV gene into expression vectors (e.g., plasmids) and overexpressing it in host systems like *E. coli*. This allows large-scale purification of the protein for functional studies. Recombinant technology enables modifications such as affinity tags (e.g., His-tag) for easier isolation, solubility enhancement, or site-specific mutations to investigate structure-function relationships. The purified protein retains biological activity, facilitating in vitro assays to study ribosome assembly, antibiotic resistance mechanisms, or interactions with translation factors.
Research on recombinant L22 has provided insights into bacterial ribosome biogenesis and antibiotic targeting. It serves as a tool for structural biology (e.g., X-ray crystallography, cryo-EM) to visualize ribosome dynamics and drug-binding sites. Additionally, engineered L22 variants help explore evolutionary conservation of ribosomal functions and develop novel antibacterial strategies. Its role in clinical antibiotic resistance, particularly in pathogens like *Staphylococcus aureus*, underscores its biomedical relevance. Recombinant rplV protein thus bridges basic ribosomal research and applied microbiological applications, offering a model to dissect translation mechanisms and therapeutic interventions.
×
